Joint Formulary & PAD

Safinamide - Parkinson's disease

You are here : Home > Formulary Search > Safinamide - Parkinson's disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :

Documentation

Evidence Review
Safinamide - Application for Change in colour classification - Nov 25

PAD Profile

ChemicalSubstance :
Safinamide
Indication :
Parkinson's disease
Group Name :
Keywords :
PD
Brand Names Include :
Xadago
Important Information :

Initiaition and a minimum of 1 month supply by the specialis team before any request is made for transfer of prescribing responsibility.

Safinamide has been agreed for use as a last line oral treatment option for its licensed indication in PD patients who:

  • are contraindicated to, have failed or cannot tolerate rasagiline or selegiline (after an adequate trial), OR
  • are considered for advanced, non-oral treatments e.g. deep brain stimulation, apomorphine and levodopa/carbidopa intestinal gel (LCIG).
Latest Additions Date From :
21 Nov 2025
Latest Additions Date To :
26 Dec 2025
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

05 Nov 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a change in traffic light status for safinamide for use in patients with Parkinson’s Disease.

Safinamide for this indication will be given a BLUE (with specialist team initiation) traffic light status. Specialist teams should prescribe for at least 1 month prior to transfer of care.

For use as a last line oral treatment option for its licensed indication in Parkinson’s Disease, when patients are contraindicated to, have failed or cannot tolerate rasagiline or selegiline (after an adequate trial), OR for patients considered for advanced, non-oral treatments e.g. deep brain stimulation, apomorphine and levodopa/carbidopa intestinal gel (LCIG).

Other Indications

Below are listed other indications that Safinamide is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Parkinson's disease.